Quarterly ResultAug 13, 2026, 04:19 PM
Eton Pharma Q2 Revenue +99% to $37.6M; Raises FY26 Guidance
AI Summary
Eton Pharmaceuticals, Inc. reported strong financial results for the second quarter ended June 30, 2026, with product sales surging 99% year-over-year to $37.6 million. The company achieved a GAAP fully diluted EPS of $0.35 and an Adjusted EBITDA of $16.2 million. Following this performance, Eton raised its full-year 2026 revenue guidance to over $145 million and its Adjusted EBITDA margin guidance to at least 35%. Key business highlights included the successful relaunch of HEMANGEOL®, the acquisition of product candidate ASN-001 and orphan drug IMPAVIDO®, and progress in its development pipeline with FDA Fast Track designation for AMGLIDIA®.
Key Highlights
- Q2 2026 product sales reached $37.6 million, a 99% increase year-over-year.
- Reported Q2 2026 GAAP fully diluted EPS of $0.35 and non-GAAP fully diluted EPS of $0.43.
- Q2 2026 Adjusted EBITDA was $16.2 million, or 43% of revenue, up from $3.1 million in Q2 2025.
- Raised full-year 2026 revenue guidance to exceed $145 million, up from over $120 million.
- Increased full-year 2026 Adjusted EBITDA margin guidance to at least 35%, from at least 30%.
- Successfully relaunched HEMANGEOL® with patient conversion completed ahead of schedule.
- Acquired late-stage product candidate ASN-001 and U.S. commercialization rights to orphan drug IMPAVIDO®.
- Received FDA Fast Track designation for AMGLIDIA® and submitted PAS for KHINDIVI® label expansion.
Price Impact
More from ETON